key: cord-0894676-gslsunwb
authors: Jacobson, Karen B; Rao, Mallika; Bonilla, Hector; Subramanian, Aruna; Hack, Isabelle; Madrigal, Martina; Singh, Upinder; Jagannathan, Prasanna; Grant, Philip
title: Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic
date: 2021-02-07
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab103
sha: 6e40bff5f35cdc5a822af01dcd6f7f851e6a6caa
doc_id: 894676
cord_uid: gslsunwb

To assess the prevalence of persistent functional impairment after COVID-19, we assessed 118 individuals 3-4 months after their initial COVID-19 diagnosis with a symptom survey, work productivity and activity index questionnaire, and 6-minute walk test. We found significant persistent symptoms and functional impairment, even in non-hospitalized patients with COVID-19.

To date, >25 million Americans have been diagnosed with SARS-CoV-2. 1 Most infections are mild/moderate with 8-15% of patients requiring hospitalization 2 . In mild cases, two-thirds return to baseline after a median of 7 days. 3 However, symptoms can persist months after infection. "Long COVID" has been reported in 87% of hospitalized patients two months post-infection 4 and in 53% of non-hospitalized patients 125 days after diagnosis. 5 The most common persistent symptoms are fatigue, hyposmia/dysgeusia, dyspnea, arthralgias, and myalgias. [4] [5] [6] The degree of impairment in "Long COVID", or if long-term symptoms are equally prevalent in hospitalized vs. non-hospitalized COVID-19 patients, is unknown.

This study compared ongoing symptoms and functional impairment in hospitalized vs. nonhospitalized COVID-19 patients.

Patients recruited after PCR-confirmed COVID-19 infection were invited to return for long-term follow-up visits 3-4 months post-COVID-19 diagnosis. The majority were enrolled in clinical trials at Stanford at disease onset including trials of Pegnterferon-lambda (NCT04331899) or Favipiravir (NCT04346628) in non-hospitalized patients, and the Gilead SIMPLE trial (NCT04292899) for hospitalized patients. Patients were then enrolled in one of two long-term follow-up studies:

Pegnterferon-lambda's optional long-term follow-up and the IRIS Study which recruited a convenience sample of hospitalized and non-hospitalized patients at Stanford who agreed to participate after being contacted by IRIS's Study Coordinator. At follow-up, a detailed medical history including comorbidities, targeted physical exam, survey of symptoms present at time of follow-up, Work Productivity and Impairment (WPAI) questionnaire, and 6-minute walk test were A c c e p t e d M a n u s c r i p t completed. These protocols were approved by the Stanford Institutional Review Board. Participants provided written informed consent.

We used Chi-square, Fischer's exact and independent samples t-tests to compare characteristics of hospitalized vs. non-hospitalized patients. Outcomes assessed at follow-up were 1) presence of >=2 symptoms, 2) any activity impairment, and 3) percent of expected distance achieved on 6-minute walk test. 7 Logistic and linear regression models examined factors associated with these outcomes.

As of November 2020, 118 patients completed follow-up visits a median of 119.3 days after initial COVID-19 diagnosis. Overall, twenty-two (18.6%) were hospitalized for a median of 7.5 days (IQR 5-16); of these, 11 (55%) were admitted to the ICU and 6 (27%) were intubated. Hospitalized patients were more likely to be older, non-white, and have comorbid medical conditions than nonhospitalized (Table 1) . At COVID-19 onset (date of first positive test), most prevalent symptoms were fatigue (85.6%), cough (74.6%), loss of taste/smell (74.6%), and fever/chills (62.7%). Fever/chills (95.5% vs 55.2%, p<0.001) and dyspnea (50.0% vs 21.1%, p<0.001) were more prevalent in hospitalized patients vs. non-hospitalized patients. Table 2 ). Table 3 ).

A c c e p t e d M a n u s c r i p t

We describe the prevalence of persistent symptoms and impairment in work and activity and cardiopulmonary function in patients 3-4 months after COVID-19 infection.

The majority had mild/moderate COVID-19 with only 22/118 (18.6%) hospitalized during initial illness. Hospitalized patients were older and more likely to be non-white. Hospitalized patients had higher incidence of fever/chills and dyspnea at onset of COVID-19 with the most common symptoms being fatigue, cough, and anosmia, consistent with descriptions of acute COVID-19. 2 At 3-4 month follow-up, the most common persistent symptoms were fatigue, dyspnea and anosmia, consistent with other reports. [4] [5] [6] We also noted significant memory problems (17%) and hair loss (12%) at follow-up. Some of these symptoms are similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), defined by severe and incapacitating fatigue not relieved by rest, post-exertional malaise, unrefreshing sleep, severe cognitive dysfunction, pain, and autonomic dysfunction lasting for > 6 months. Such symptoms have been, in part, attributed to mitochondrial dysfunction and metabolic changes. 8 Whether "Long COVID" has a similar pathophysiology as ME/CFS remains to be determined. 8, 9 Continued follow-up of these patients will be important to determine final duration of symptoms and further elucidate risk factors and strategies for their mitigation.

Other objective findings in "Long COVID" include myocarditis 2-3 months after diagnosis 10 , which may explain the poor performance of this cohort on the 6-minute walk test relative to the expected value based on their gender and age 7 ; further cardiopulmonary testing is planned for this cohort.

A c c e p t e d M a n u s c r i p t Two-thirds of patients had at least one symptom at follow-up, half had at least two, and one-third had three or more. On the WPAI, a validated instrument measuring health-related impairments on work productivity and non-work-related activity 11 , 11.5% of currently employed patients missed work and 38.9% reported impairment at work due to health; half of all patients, including those not currently employed, reported health-related impairment in daily activities. Presence of ongoing long-term symptoms or work impairment did not differ by initial hospitalization status, though hospitalized patients were more likely to have non-work-related activity impairment. Unlike findings in other studies, we did not find an association between sex and presence of persistent symptoms.

It is striking that persistent symptoms and impairment ~4 months after COVID-19 infection were so common, especially since the majority of this cohort did not have complicated COVID-19 and few had risk factors such as underlying heart or lung disease. Much attention has been paid to the acute mortality and morbidity of COVID-19, and it is well recognized that there will be lingering health effects after critical illness. 12 A c c e p t e d M a n u s c r i p t This study has several limitations. Due to logistical issues related to recruitment, hospitalized patients had longer time between COVID-19 diagnosis and follow-up. However, despite this longer time to follow-up, hospitalized patients also achieved lower percent of expected 6-minute walk test distance and were more likely to report health-related activity impairment. Patients were recruited from two separate long-term follow-up studies with slightly different data collection procedures, however 24 patients participated in both studies and results were consistent between both studies for these patients. The small number of patients not recruited from a clinical trial did not have symptoms assessed at the time of COVID-19 onset, therefore recall bias is a concern. Selection bias is possible, as patients electing to participate in follow-up visits after COVID-19 may have more persistent symptoms than the average patient. Generalizability of results is limited given this is a single-institution study; further, patients with more mild or asymptomatic disease may have been less likely to test for COVID-19 and enroll in trials early in the pandemic with limitations in testing availability. We did not collect baseline WPAI and 6-minute walk tests, which would have allowed us to compare assessments over time within individuals.

Persistent symptoms 3-4 months after COVID-19 diagnosis was common with similar levels in hospitalized vs. non-hospitalized patients. Functional impairment at long-term follow-up was higher in hospitalized patients but also prevalent in non-hospitalized patients. With burgeoning cases throughout the country, there is concern for significant morbidity due to persistent symptoms and functional impairment even in patients with uncomplicated COVID-19 and efforts to dissect the cause and mitigate the impact are needed.

A c c e p t e d M a n u s c r i p t NOTES M a n u s c r i p t A c c e p t e d M a n u s c r i p t

Missed work due to health Any Work Impairment due to health Any Activity impairment due to health

COVID-19 Dashboard by the Center for Systems Science and Engineering

The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

Persistent Symptoms in Patients After Acute COVID-19

Long COVID in the Faroe Islands -a longitudinal study among non-hospitalized patients

Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study

Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years

Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 'long-haulers'?

Emerging Neurological and Psychobiological Aspects of COVID-19 Infection

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease

A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective

Post-intensive Care Syndrome: an Overview

IQR=interquartile range. P value represents Chi-square, Fisher's exact test or independent samples t-test as appropriate

] where best 6MWD is expressed in meters, age is in years and gender is "women = 1" and "men = 0"; Percent of expected distance = Distance in meters ÷ Expected distance x 100

We would like to thank the participants of both the IRIS and Lambda long-term follow-up studies.We are grateful to the study teams for their hard work.

The Lambda study was funded by anonymous donors to Stanford University. The IRIS Study was funded by an internal grant at Stanford though ChEM-H. Additional support was provided by NIH/NIAID (U01 AI150741-01S1 (to P.J.)None of the authors has potential conflicts of interest to disclose.

A c c e p t e d M a n u s c r i p t